Potential drug decreased viral load in patients with various HCV genotypes - Healio
/In the trial, currently taking place in the Netherlands, RG-101 (Regulus Therapeutics), a GalNac-conjugated anti-miR targeting microRNA-122, was dosed at 2 mg/kg and given to 14 patients with HCV and various genotypes. This treatment resulted in ...>
from HCV - Google News http://ift.tt/1zAFZV8 via IFTTT